PanGen-Fam: Spanish Registry of Hereditary Pancreatic Cancer
Overview
Authors
Affiliations
Purpose: To describe the organisation of the registry and the preliminary results in terms of characteristics of high-risk pancreatic ductal adenocarcinoma (PDAC) families recruited to date and findings of the screening programme. To compare early onset sporadic cases (⩽50 years), sporadic cases (>50 years) and cases with family history of cancer, for PDAC possible risk factors.
Methods/patients: Families with hereditary cancer syndromes predisposing to PDAC were recruited from two main sources: Spanish hospitals participating in PanGenEU, a pan-European multicentre case-control study, and their genetic counseling unit. Individuals at high-risk of PDAC were enrolled into a screening programme, consisting of Endoscopic ultrasound, computerised tomography, magnetic resonance imaging. Genetic testing of candidate genes was offered according to each patient's risk.
Results: Among 577 consecutive PDAC cases, recruited via PanGenEU, 36 (6%) had ⩾2 first-degree relative with PDAC: Familial pancreatic cancer (FPC). So far PanGen-Fam has recruited 42 high-risk PDAC families; 25 (60%) had FPC. Five index cases with cancer were positive for BRCA2 and one for BRCA1 germline mutations. In the second year of prospective PDAC screening, one neuroendocrine tumour and a high-grade dysplasia lesion suspicious of carcinoma were diagnosed among 41 high-risk individuals. Furthermore EUS detected chronic-pancreatitis-like parenchymal changes in 15 patients.
Concluding Statement: The identification and recruitment of PDAC high-risk families into the PanGen-Fam registry provides an opportunity to detect early onset cancer and precursor pancreatic cancer lesions at a potentially curative stage and to increase the knowledge of the natural history of the disease.
Cristina-Marianini-Rios , Sanchez M, Garcia Garcia de Paredes A, Rodriguez M, Barreto E, Lopez J Fam Cancer. 2024; 23(3):233-246.
PMID: 38780705 PMC: 11254992. DOI: 10.1007/s10689-024-00397-w.
Earl J, Fuentes R, Sanchez M, Garcia Garcia de Paredes A, Munoz M, Sanjuanbenito A Fam Cancer. 2024; 23(3):383-392.
PMID: 38753287 PMC: 11254983. DOI: 10.1007/s10689-024-00388-x.
Aspects and outcomes of surveillance for individuals at high-risk of pancreatic cancer.
Bogdanski A, van Hooft J, Boekestijn B, Bonsing B, Wasser M, Klatte D Fam Cancer. 2024; 23(3):323-339.
PMID: 38619782 PMC: 11255004. DOI: 10.1007/s10689-024-00368-1.
The role of endoscopic ultrasound in the detection of pancreatic lesions in high-risk individuals.
Overbeek K, Cahen D, Bruno M Fam Cancer. 2024; 23(3):279-293.
PMID: 38573399 PMC: 11255057. DOI: 10.1007/s10689-024-00380-5.
Archibugi L, Casciani F, Carrara S, Secchettin E, Falconi M, Capurso G Fam Cancer. 2024; 23(3):373-382.
PMID: 38493228 DOI: 10.1007/s10689-024-00366-3.